Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 74, Issue 5, 2000, Pages 255-259

  Graham, J Dinny ^a   Bain, David L ^a   Richer, Jennifer K ^a   Jackson, Twila A ^a   Tung, Lin ^a   Horwitz, Kathryn B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms; Estrogen receptors; Progesterone; Steroid receptors; Tamoxifen; Transcriptional coregulators

Indexed keywords

ANTIESTROGEN; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; NUCLEAR RECEPTOR COREPRESSOR; PROGESTERONE RECEPTOR; PROTEIN L7 SPA; PROTEIN SMRT; REGULATOR PROTEIN; REPRESSOR PROTEIN; STEROID RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DNA BINDING; GROWTH INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PROTEIN PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; REPRESSOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR RECURRENCE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; MIFEPRISTONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; TAMOXIFEN; TRANSCRIPTION FACTORS;

CLUPEA HARENGUS;

EID: 0034735870     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00101-1     Document Type: Conference Paper

References (49)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
2. Hormone receptors: Their role in predicting prognosis and response to endocrine therapy
3. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective southwest oncology group study
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4 hydroxytamoxifen
6. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients
7. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen resistant human breast tumors
8. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
9. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer
10. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β 1 in metastatic human breast cancer: An immunocytochemical study
11. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
12. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
13. Tamoxifen-induced tumor stimulation and withdrawal response
14. Clinical significance of tamoxifen withdrawal response
15. Tamoxifen withdrawal response
16. When tamoxifen turns bad
17. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
18. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice
19. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
20. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
21. Nuclear receptor coactivators and corepressors
22. Nuclear receptor coactivators
23. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
24. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
25. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
26. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
27. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
28. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription
29. The nuclear hormone coactivator SRC-1 is a specific target of p300
30. Steroid receptor coactivator-1 is a histone acetyltransferase
31. The transcriptional coactivators p300 and CBP are histone acetyltransferases
32. The CBP coactivator is a histone acetyltransferase
33. CREB-binding protein activates transcription through multiple domains
34. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
35. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
36. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
37. A transcriptional co-repressor that interacts with nuclear hormone receptors
38. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors
39. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
40. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
41. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
42. What's up and down with histone deacetylation and transcription?
43. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions
44. Peptide antagonists of the human estrogen receptor
45. Atomic structure of progesterone complexed with its receptor
46. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
47. The N-terminal region of the human progesterone A-receptor: Structural analysis and the influence of the DNA binding domain
48. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene